AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1403464 — intervention group
Group type: EXPERIMENTAL
Intervention: GI priming plus TPN
Number of subjects: 40
Study 1403464 — intervention group
Group type: COMPARATOR
Intervention: TPN alone
Number of subjects: 40
Study 3892406 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 174
Study 3892406 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 174
Study 3892406 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 174
Study 3892406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 3296967 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 30
Study 3296967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31477545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination, low-dose, triple-pill antihypertensive therapy (amlodipine, telmisartan, chlorthalidone)
Number of subjects: 0
Study 31477545 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amphotericin B (2.5 mg)
Number of subjects: 40
Study 25466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (0.5 mg)
Number of subjects: 40
Study 23419053 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) delivered by community pharmacists, consisting of a brief motivational discussion lasting approximately 10 minutes.
Number of subjects: 0
Study 23419053 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control condition, where participants receive an alcohol information leaflet with no opportunity for discussion.
Number of subjects: 0
Study 21464720 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 4 weeks
Number of subjects: 34
Study 21464720 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg for 4 weeks
Number of subjects: 34
Study 21464720 — intervention group
Group type: COMPARATOR
Intervention: No PPI
Number of subjects: 34
Study 18769636 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pharmacological treatment modalities for TBI
Number of subjects: 1500000
Study 18769636 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic and clinical research findings
Number of subjects: 1500000
Study 18769636 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective clinical trials
Number of subjects: 1500000
Study 16790647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 16790647 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 12394678 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized mentored instruction
Number of subjects: 20
Study 12394678 — intervention group
Group type: COMPARATOR
Intervention: No additional training
Number of subjects: 20
Study 10709673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind (Sulindac sulfone) 200 mg, 300 mg, or 400 mg twice daily for six months
Number of subjects: 18
Study 10709673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind (Sulindac sulfone) at all dose levels
Number of subjects: 18
Study 10709673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exisulind (Sulindac sulfone)
Number of subjects: 18
Study 7596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm IV: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐fluorouracil (5‐FU) 200 mg/body/day p.o. for six months
Number of subjects: 1805
Study 7596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm V: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Number of subjects: 1805
Study 7596054 — intervention group
Group type: COMPARATOR
Intervention: Arm VI: surgery alone (control)
Number of subjects: 1805
Study 7596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm I: mitomycin C (intraoperative portal vein bolus 12 mg/m2 + postoperative, twice weekly and then three times bimonthly for six months intermittent i.v. bolus 6 mg/m2) + 5‐FU 200 mg/body/day p.o. for six months
Number of subjects: 1805
Study 7596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm II: postoperative twice weekly and then three times bimonthly intermittent i.v. bolus mitomycin C (6 mg/m2) for six months + 5‐FU 200 mg/body/day p.o. for six months
Number of subjects: 1805
Study 7596054 — intervention group
Group type: COMPARATOR
Intervention: Arm III: surgery alone (control)
Number of subjects: 1805
Study 7596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes C patients in Arm II: postoperative treatment
Number of subjects: 1805
Study 7596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm I: Dukes C patients
Number of subjects: 1805
Study 7596054 — intervention group
Group type: COMPARATOR
Intervention: Arm III: surgery alone (control) for Dukes C patients
Number of subjects: 1805
Study 2185045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal aspiration of ascitic fluid guided by ultrasound
Number of subjects: 11
Study 2185045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 474432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide
Number of subjects: 26
Study 474432 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 26
Study 31794974 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-weeks active intermittent theta burst stimulation (iTBS)
Number of subjects: 46
Study 31794974 — intervention group
Group type: COMPARATOR
Intervention: 2-weeks sham stimulation
Number of subjects: 46
Study 29949473 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-stable carbetocin (100 μg)
Number of subjects: 29645
Study 29949473 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 IU)
Number of subjects: 29645
Study 26908570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor augmented pump therapy with low glucose insulin suspension
Number of subjects: 38
Study 26908570 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor accuracy
Number of subjects: 38
Study 24102867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of hydroxyapatite and autogenous bone (80:20 w/w)
Number of subjects: 10
Study 24102867 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 10
Study 22833010 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal handgrip contraction (100% MVC)
Number of subjects: 0
Study 22833010 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal handgrip contraction (30% MVC)
Number of subjects: 0
Study 20724560 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation (10-day program at ∼50% VO2max in 40°C)
Number of subjects: 12
Study 20724560 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 matched subjects, identical exercise in cool environment)
Number of subjects: 12
Study 18981499 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (Artequin)
Number of subjects: 470
Study 18981499 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (Coartem)
Number of subjects: 470
Study 16737798 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive Enhancement Therapy with Work Therapy (NET+WT)
Number of subjects: 152
Study 16737798 — intervention group
Group type: COMPARATOR
Intervention: Work Therapy only (WT only)
Number of subjects: 152
Study 12651805 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP450 GeneChip assay
Number of subjects: 236
Study 12651805 — intervention group
Group type: EXPERIMENTAL
Intervention: AS‐PCR
Number of subjects: 236
Study 12651805 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 subgroups (PM, IM, EM, UM)
Number of subjects: 236
Study 10371095 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (1 mg/kg per body weight per day)
Number of subjects: 0
Study 10371095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9049968 — intervention group
Group type: EXPERIMENTAL
Intervention: VACPE regimen (vincristine 2 mg d1, adriamycin 25 mg/m2 d1-3, cyclophosphamide 800 mg/m2 d1, prednisone 60 mg/m2 d1-7, etoposide 120 mg/m2 d1-3)
Number of subjects: 27
Study 9049968 — intervention group
Group type: EXPERIMENTAL
Intervention: VACPE regimen
Number of subjects: 27
Study 1910957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclic etidronate (400 mg/day oral for 2 weeks, followed by 13 weeks off treatment)
Number of subjects: 37
Study 1910957 — intervention group
Group type: COMPARATOR
Intervention: ADFR treatment (100 micrograms/day oral triiodothyronine for 7 days, followed by 400 mg/day etidronate for 2 weeks and 12 weeks off treatment)
Number of subjects: 37
Study 7102850 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person interviews
Number of subjects: 546
Study 7102850 — intervention group
Group type: COMPARATOR
Intervention: Telephone interviews
Number of subjects: 546
Study 31481560 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic carbohydrate counting programme
Number of subjects: 231
Study 31481560 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced carbohydrate counting programme including an automated bolus calculator
Number of subjects: 231
Study 31481560 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary care
Number of subjects: 231
Study 31481560 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 231
Study 30636761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 117
Study 30636761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 27290676 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 525
Study 27290676 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES)
Number of subjects: 525
Study 23730718 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy support at 6 months
Number of subjects: 201
Study 23730718 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous self-regulation at 6 months
Number of subjects: 201
Study 23730718 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement of healthy eating at 6 months
Number of subjects: 201
Study 23730718 — intervention group
Group type: EXPERIMENTAL
Intervention: Other forms of directive support
Number of subjects: 201
Study 22885681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mussel-mimetic tissue adhesive (mussel glue)
Number of subjects: 0
Study 22885681 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 0
Study 20977850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg, once a day for 3-8 days
Number of subjects: 105
Study 20977850 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) 0.4 ml, twice a day for 3-8 days
Number of subjects: 105
Study 20977850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 105
Study 20977850 — intervention group
Group type: COMPARATOR
Intervention: LMWH
Number of subjects: 105
Study 18762476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (100 mg daily)
Number of subjects: 3350
Study 18762476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3350
Study 15700050 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin ('Zoladex') injection using 16-gauge needle
Number of subjects: 50
Study 15700050 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin ('Prostap') injection using 23-gauge needle
Number of subjects: 50
Study 15700050 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin ('Zoladex') injection
Number of subjects: 50
Study 15700050 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin ('Prostap') injection
Number of subjects: 50
Study 12581262 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg intravenous infusion)
Number of subjects: 17
Study 12581262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10479672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluindione at INR 1.5 to 2.0
Number of subjects: 10
Study 10479672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluindione at INR 2.1 to 3.0
Number of subjects: 10
Study 10479672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluindione plus aspirin (325 mg/d)
Number of subjects: 10
Study 10479672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluindione plus aspirin
Number of subjects: 10
Study 8792753 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 129
Study 8792753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 1624004 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration (2,500 U two times weekly between the 4th and 8th week of gestation)
Number of subjects: 447
Study 1624004 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration in hMG/hCG generated gestations
Number of subjects: 447
Study 1624004 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration in CC/hCG-induced pregnancies
Number of subjects: 447
Study 1624004 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration in spontaneous conceptions
Number of subjects: 447
Study 6342220 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange on six consecutive days at a mean exchange volume of 40.6 ml/kg of body weight each day
Number of subjects: 27
Study 6342220 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression only
Number of subjects: 27
Study 29702502 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri‐operative oral caffeine (400 mg every 8 h for 2 days)
Number of subjects: 110
Study 29702502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 27484013 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine
Number of subjects: 326
Study 27484013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 27484013 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 326
Study 25237116 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 300 mg/day
Number of subjects: 21
Study 25237116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25237116 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 75 mg/day
Number of subjects: 21
Study 22261900 — intervention group
Group type: EXPERIMENTAL
Intervention: brief monthly CPR practice with voice‐activated manikins
Number of subjects: 606
Study 22261900 — intervention group
Group type: COMPARATOR
Intervention: no practice
Number of subjects: 606
Study 20924214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime alcohol intake of more than 292 kg
Number of subjects: 146
Study 20924214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative alcohol intake
Number of subjects: 146
Study 20924214 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of heavy drinkers
Number of subjects: 146
Study 20924214 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake
Number of subjects: 146
Study 17986302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Number of subjects: 84
Study 17986302 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 84
Study 15979768 — intervention group
Group type: EXPERIMENTAL
Intervention: Single morning dose (400 ml) of carbohydrate-rich drink (CL)
Number of subjects: 6
Study 15979768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of the drink in the evening and in the morning before the clamp (LL)
Number of subjects: 6
Study 15979768 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasting (CC)
Number of subjects: 6
Study 15979768 — intervention group
Group type: COMPARATOR
Intervention: Single evening dose (800 ml) of carbohydrate-rich drink (LC)
Number of subjects: 6
Study 11937141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook Echo-Tip catheter
Number of subjects: 251
Study 11937141 — intervention group
Group type: COMPARATOR
Intervention: Wallace catheter
Number of subjects: 251
Study 10518228 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptives with different progestogen types (desogestrel, gestodene, levonorgestrel, norgestimate) and ethinyl estradiol doses (50, 30, and 20 micrograms)
Number of subjects: 730
Study 8198904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 300 micrograms, 1 h before and 12 h after surgery
Number of subjects: 40
Study 8198904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 8198904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine
Number of subjects: 40
Study 8198904 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine and placebo
Number of subjects: 40
Study 2452308 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-10
Number of subjects: 67
Study 2452308 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-20
Number of subjects: 67
Study 2452308 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-40
Number of subjects: 67
Study 2452308 — intervention group
Group type: COMPARATOR
Intervention: Normal left ventricular function (control group)
Number of subjects: 67
Study 29655700 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols
Number of subjects: 80
Study 27251519 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage posterior sagittal anorectoplasty (PSARP)
Number of subjects: 40
Study 27251519 — intervention group
Group type: COMPARATOR
Intervention: Three-stage operation (colostomy, PSARP, and closure of colostomy)
Number of subjects: 40
Study 24297318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT‐based intervention)
Number of subjects: 15
Study 24297318 — intervention group
Group type: COMPARATOR
Intervention: Deferred‐entry control group (CG)
Number of subjects: 15
Study 21511980 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Number of subjects: 39
Study 20507376 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 27
Study 20507376 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 27
Study 20507376 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser + SRP
Number of subjects: 27
Study 20507376 — intervention group
Group type: COMPARATOR
Intervention: Supragingival scaling
Number of subjects: 27
Study 18657134 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of lactose
Number of subjects: 77
Study 18657134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 16188753 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume packed red blood cell (PRBC) transfusions (20 ml/kg)
Number of subjects: 20
Study 16188753 — intervention group
Group type: COMPARATOR
Intervention: Standard volume packed red blood cell (PRBC) transfusions (15 ml/kg)
Number of subjects: 20
Study 12153814 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosurgical DCR
Number of subjects: 69
Study 12153814 — intervention group
Group type: COMPARATOR
Intervention: Endolaser (Holmium:YAG) DCR
Number of subjects: 69
Study 12153814 — intervention group
Group type: COMPARATOR
Intervention: Lacrimal irrigation
Number of subjects: 69
Study 12153814 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic dye test (FEDT)
Number of subjects: 69
Study 10341394 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP) therapy, performed 3 times with 1 week intervals between procedures.
Number of subjects: 0
Study 10341394 — intervention group
Group type: COMPARATOR
Intervention: Sham procedures (Control group)
Number of subjects: 0
Study 8862491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (400 micrograms/day)
Number of subjects: 22
Study 8862491 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (900 micrograms/day)
Number of subjects: 22
Study 8862491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 22
Study 8862491 — intervention group
Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 22
Study 1994844 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal iodine supplementation during pregnancy
Number of subjects: 0
Study 1994844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 6188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 6188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0
Study 6188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0
Study 6188922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0
Study 31477439 — intervention group
Group type: COMPARATOR
Intervention: Tübingen palatal plate (TPP)
Number of subjects: 443
Study 31477439 — intervention group
Group type: COMPARATOR
Intervention: Prone positioning
Number of subjects: 443
Study 27943220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg/kg, to a maximum of 4 mg)
Number of subjects: 145
Study 26931195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisation in an SSU (intervention)
Number of subjects: 430
Study 26931195 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Department of Internal Medicine) (control)
Number of subjects: 430
Study 25151200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202
Study 25151200 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202
Study 25151200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study 25151200 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole vs Ziprasidone
Number of subjects: 202
Study 25151200 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole vs Quetiapine
Number of subjects: 202
Study 25151200 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine vs Ziprasidone
Number of subjects: 202
Study 25151200 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 202